Developer docs
API playgroundTry for free, no card

Search company profiles

ProGnosis Biotech

Full company profile

uuid000ebm7

Namestring
ProGnosis Biotech
Company typeenum
Private
Founded yearint
2011
Descriptiontext

ProGnosis Biotech is a Greek-headquartered, privately held biotechnology company founded in 2011, operating in Lárissa with a headcount of 51-100 employees. The company develops next-generation immunoassays for clinical and food-safety diagnostics, with its current disclosed focus on diagnostic solutions for mycotoxin detection and control across the dairy supply chain — specifically aflatoxin B1 and M1 contamination, where its offering is differentiated on accuracy and precision.

The company's revenue model is built around hardware sales of diagnostic products (testing kits and related analytical services), targeting dairy producers, processors, and feed suppliers as its primary vertical. Go-to-market is event-driven, with engagement through industry conferences aimed at dairy-chain stakeholders in Serbia and the broader Balkans region. The strategic emphasis is positioned around Serbia's forthcoming alignment with the stricter EU mycotoxin threshold of 0.05 μg/kg, effective 1 December 2026, which creates an immediate compliance-driven demand for faster diagnostics and feed-risk management.

Material data gaps limit further characterization: no patents, certifications, named customer accounts, management team, funding history, or revenue figures are disclosed in the available sources. The company's own website currently displays only a verification/loading page, and the only documented activity in the source set is a March 2026 industry conference in Serbia. Ownership, investor backing, and product roadmap beyond aflatoxin diagnostics are not characterized.

Short descriptiontext

ProGnosis Biotech is a Greek biotechnology company developing next-generation immunoassays for mycotoxin diagnostics, primarily serving dairy producers, processors, and feed suppliers in the Balkans ahead of Serbia's December 2026 EU regulatory alignment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLárissa, Greece
HQ citystring
Lárissa
HQ countrystring
Greece
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
mycotoxin detection assays, aflatoxin immunoassays, dairy safety diagnostics, food safety testing, clinical diagnostic kits
Industry3 codes
PRIMARYAFALAFAC
Mycotoxin Testing (Aflatoxins, Ochratoxin, DON, ZEN, Fumonisins)
Agriculture & Food Production/Food Safety, Testing & Certification/Residue & Contaminant Testing (Pesticides, Veterinary Drugs, Mycotoxins, Heavy Metals)
SECONDARYAFALAAAF
Residue & Contaminant Testing (Pesticides, Vet Drugs, Mycotoxins, Heavy Metals)
Agriculture & Food Production/Food Safety, Testing & Certification/Food Testing Laboratories (Microbiological, Chemical, Allergen)
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Testing Laboratories8734
Product category
Mycotoxin Diagnostic Testing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Products and Services
TypeHardware Sales
Description

ProGnosis Biotech provides diagnostic solutions for mycotoxin detection in the dairy supply chain, likely offering testing kits, analytical services, and advisory solutions for feed-risk management and compliance with EU mycotoxin thresholds.

agroberichtenbuitenland.nl
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ProGnosis Biotech develops next-generation immunoassays for clinical diagnostics, specializing in mycotoxin detection and control across the dairy supply chain. The company provides diagnostic solutions for detecting and controlling aflatoxin B1 and M1 contamination, enabling dairy producers, processors, and feed suppliers to meet EU food safety regulations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Serbia aligning with EU mycotoxin threshold of 0.05 μg/kg from 1 December 2026
Product overview1 text field

Based on the available source data, ProGnosis Biotech appears to operate in the agricultural/food safety technology sector, specifically focused on mycotoxin detection and control solutions. The news source indicates they held a conference addressing aflatoxin B1 and M1 control across the dairy chain, highlighting expertise in dairy safety diagnostics. However, no specific named products, modules, or service offerings are detailed in the provided source material.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in food and feed testing services with extensive mycotoxin analytical capabilities and reference laboratories. Competes with ProGnosis Biotech as a comprehensive food-safety services provider.

TypeDirect peer
Description

European diagnostics company (formerly EuroProxima) producing ELISA kits for mycotoxins, veterinary drugs, and other contaminants. Closely comparable niche-specialist profile to ProGnosis Biotech.

TypeBroad incumbent
Description

Global inspection, verification, and testing company with a sizable food and agricultural testing division. Operates as a broad incumbent offering mycotoxin analysis among many other services.

TypeBroad incumbent
Description

Large diagnostics and life science company with immunoassay products and food safety testing reagents. Comparable in immunoassay technology base, though operating across much broader portfolios.

TypeDirect peer
Description

German diagnostics company specializing in ELISA and lateral flow test kits for mycotoxin detection in food and feed. Directly comparable to ProGnosis Biotech in core immunoassay technology and aflatoxin focus.

TypeBroad incumbent
Description

Global analytical instruments and diagnostics company with food safety testing reagents and instruments. Operates broadly in the same analytical technology space as ProGnosis Biotech.

TypeDirect peer
Description

Austrian-based subsidiary of ERBER Group focused on mycotoxin testing kits and analytical services for the food and feed industry. Closely comparable product portfolio and customer base to ProGnosis Biotech.

TypeDirect peer
Description

US-based food safety diagnostics company offering a broad portfolio of test kits for mycotoxins, allergens, and pathogens. Comparable product category and target end-markets to ProGnosis Biotech.

9VICAM
TypeDirect peer
Description

Specialist in aflatoxin and mycotoxin testing solutions with a long-standing focus on immunoaffinity columns and rapid test kits. Directly comparable in aflatoxin diagnostic technology and target customers.

TypeEmerging player
Description

China-based immunoassay kit manufacturer with a growing catalog of mycotoxin and food safety ELISA kits. Comparable as an emerging specialist targeting similar buyers in food safety.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ProGnosis Biotech

Mycotoxin Diagnostic Testingprognosis-biotech.com

ProGnosis Biotech is a Greek biotechnology company developing next-generation immunoassays for mycotoxin diagnostics, primarily serving dairy producers, processors, and feed suppliers in the Balkans ahead of Serbia's December 2026 EU regulatory alignment.

What ProGnosis Biotech does

ProGnosis Biotech is a Greek-headquartered, privately held biotechnology company founded in 2011, operating in Lárissa with a headcount of 51-100 employees. The company develops next-generation immunoassays for clinical and food-safety diagnostics, with its current disclosed focus on diagnostic solutions for mycotoxin detection and control across the dairy supply chain — specifically aflatoxin B1 and M1 contamination, where its offering is differentiated on accuracy and precision.

The company's revenue model is built around hardware sales of diagnostic products (testing kits and related analytical services), targeting dairy producers, processors, and feed suppliers as its primary vertical. Go-to-market is event-driven, with engagement through industry conferences aimed at dairy-chain stakeholders in Serbia and the broader Balkans region. The strategic emphasis is positioned around Serbia's forthcoming alignment with the stricter EU mycotoxin threshold of 0.05 μg/kg, effective 1 December 2026, which creates an immediate compliance-driven demand for faster diagnostics and feed-risk management.

Material data gaps limit further characterization: no patents, certifications, named customer accounts, management team, funding history, or revenue figures are disclosed in the available sources. The company's own website currently displays only a verification/loading page, and the only documented activity in the source set is a March 2026 industry conference in Serbia. Ownership, investor backing, and product roadmap beyond aflatoxin diagnostics are not characterized.

ProGnosis Biotech firmographics

Firmographics
Name
ProGnosis Biotech
Website
https://prognosis-biotech.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
101–250 employees
Short description
ProGnosis Biotech is a Greek biotechnology company developing next-generation immunoassays for mycotoxin diagnostics, primarily serving dairy producers, processors, and feed suppliers in the Balkans ahead of Serbia's December 2026 EU regulatory alignment.
Ownership category
akta.pro rank

ProGnosis Biotech industry classification

Industry
Product category
Mycotoxin Diagnostic Testing
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYAFALAFAC
Mycotoxin Testing (Aflatoxins, Ochratoxin, DON, ZEN, Fumonisins)
Agriculture & Food Production/Food Safety, Testing & Certification/Residue & Contaminant Testing (Pesticides, Veterinary Drugs, Mycotoxins, Heavy Metals)
SECONDARYAFALAAAF
Residue & Contaminant Testing (Pesticides, Vet Drugs, Mycotoxins, Heavy Metals)
Agriculture & Food Production/Food Safety, Testing & Certification/Food Testing Laboratories (Microbiological, Chemical, Allergen)
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories

Keywords

  • Mycotoxin detection assays
  • Aflatoxin immunoassays
  • Dairy safety diagnostics
  • Food safety testing
  • Clinical diagnostic kits

Where ProGnosis Biotech is headquartered

Location

Headquarters

HQ city
Lárissa
HQ country
Greece
HQ region
Europe

Markets served

ProGnosis Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Diagnostic Products and Services: ProGnosis Biotech provides diagnostic solutions for mycotoxin detection in the dairy supply chain, likely offering testing kits, analytical services, and advisory solutions for feed-risk management and compliance with EU mycotoxin thresholds.

Go-to-market motion1 record

Marketing channels1 record

ProGnosis Biotech product offering

Product offering

Core offering

ProGnosis Biotech develops next-generation immunoassays for clinical diagnostics, specializing in mycotoxin detection and control across the dairy supply chain. The company provides diagnostic solutions for detecting and controlling aflatoxin B1 and M1 contamination, enabling dairy producers, processors, and feed suppliers to meet EU food safety regulations.

Product overview

Based on the available source data, ProGnosis Biotech appears to operate in the agricultural/food safety technology sector, specifically focused on mycotoxin detection and control solutions. The news source indicates they held a conference addressing aflatoxin B1 and M1 control across the dairy chain, highlighting expertise in dairy safety diagnostics. However, no specific named products, modules, or service offerings are detailed in the provided source material.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Serbia aligning with EU mycotoxin threshold of 0.05 μg/kg from 1 December 2026

Companies that use ProGnosis Biotech

Customer profile

Segments1 record

Ideal customer profiles1 record

ProGnosis Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

ProGnosis Biotech partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

ProGnosis Biotech competitors and assessment

Company assessment

Broad incumbents

  • Eurofins Scientific: Global leader in food and feed testing services with extensive mycotoxin analytical capabilities and reference laboratories. Competes with ProGnosis Biotech as a comprehensive food-safety services provider.
  • SGS SA: Global inspection, verification, and testing company with a sizable food and agricultural testing division. Operates as a broad incumbent offering mycotoxin analysis among many other services.
  • Bio-Rad Laboratories: Large diagnostics and life science company with immunoassay products and food safety testing reagents. Comparable in immunoassay technology base, though operating across much broader portfolios.
  • PerkinElmer / Revvity: Global analytical instruments and diagnostics company with food safety testing reagents and instruments. Operates broadly in the same analytical technology space as ProGnosis Biotech.

Direct peers

  • Gold Standard Diagnostics: European diagnostics company (formerly EuroProxima) producing ELISA kits for mycotoxins, veterinary drugs, and other contaminants. Closely comparable niche-specialist profile to ProGnosis Biotech.
  • R-Biopharm: German diagnostics company specializing in ELISA and lateral flow test kits for mycotoxin detection in food and feed. Directly comparable to ProGnosis Biotech in core immunoassay technology and aflatoxin focus.
  • Romer Labs: Austrian-based subsidiary of ERBER Group focused on mycotoxin testing kits and analytical services for the food and feed industry. Closely comparable product portfolio and customer base to ProGnosis Biotech.
  • Neogen Corporation: US-based food safety diagnostics company offering a broad portfolio of test kits for mycotoxins, allergens, and pathogens. Comparable product category and target end-markets to ProGnosis Biotech.
  • VICAM: Specialist in aflatoxin and mycotoxin testing solutions with a long-standing focus on immunoaffinity columns and rapid test kits. Directly comparable in aflatoxin diagnostic technology and target customers.

Emerging players

  • Elabscience: China-based immunoassay kit manufacturer with a growing catalog of mycotoxin and food safety ELISA kits. Comparable as an emerging specialist targeting similar buyers in food safety.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

ProGnosis Biotech social profiles

Digital presence

ProGnosis Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ProGnosis Biotech leadership team

Management profile

Number of profiles

ProGnosis Biotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ProGnosis Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProGnosis Biotech

What does ProGnosis Biotech do?

ProGnosis Biotech develops next-generation immunoassays for clinical diagnostics, specializing in mycotoxin detection and control across the dairy supply chain. The company provides diagnostic solutions for detecting and controlling aflatoxin B1 and M1 contamination, enabling dairy producers, processors, and feed suppliers to meet EU food safety regulations.

Is ProGnosis Biotech a public or private company?

ProGnosis Biotech is a private company. It is classified as unknown and is currently operating.

When was ProGnosis Biotech founded?

ProGnosis Biotech was founded in 2011. It employs 101 to 250 people.

Where is ProGnosis Biotech based?

ProGnosis Biotech is headquartered in Lárissa, Greece, in the Europe region.

How does ProGnosis Biotech make money?

One revenue line is on record: diagnostic Products and Services.

Who are ProGnosis Biotech's main competitors?

Broad incumbents on record are Eurofins Scientific, SGS SA, Bio-Rad Laboratories and PerkinElmer / Revvity. Direct peers are Gold Standard Diagnostics, R-Biopharm, Romer Labs, Neogen Corporation and VICAM. Elabscience is listed as an emerging player.

Does ProGnosis Biotech have an API?

No public API is recorded for ProGnosis Biotech.

What industry is ProGnosis Biotech in?

ProGnosis Biotech's product category is Mycotoxin Diagnostic Testing. Its primary akta.pro industry code is AFALAFAC, Mycotoxin Testing (Aflatoxins, Ochratoxin, DON, ZEN, Fumonisins), with a secondary code of AFALAAAF, Residue & Contaminant Testing (Pesticides, Vet Drugs, Mycotoxins, Heavy Metals). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals